Show simple item record

dc.contributor.authorJudson, I
dc.contributor.authorJones, RL
dc.contributor.authorWong, NACS
dc.contributor.authorDileo, P
dc.contributor.authorBulusu, R
dc.contributor.authorSmith, M
dc.contributor.authorAlmond, M
dc.coverage.spatialEngland
dc.date.accessioned2024-08-30T11:14:44Z
dc.date.available2024-08-30T11:14:44Z
dc.date.issued2024-06-05
dc.identifier10.1038/s41416-024-02672-0
dc.identifier.citationBritish Journal of Cancer, 2024,
dc.identifier.issn0007-0920
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/6375
dc.identifier.eissn1532-1827
dc.identifier.eissn1532-1827
dc.identifier.doi10.1038/s41416-024-02672-0
dc.identifier.doi10.1038/s41416-024-02672-0
dc.description.abstractBACKGROUND: British Sarcoma Group guidelines for the management of GIST were initially informed by those published by the European Society of Clinical Oncology. This update was written by a group of experts to includes a discussion of the highlight improvements in our knowledge of the disease and recent treatment developments. The guidelines include sections on Incidence, Aetiology, Diagnosis, including risk assessment, Treatment and Follow-up. METHODS: A careful review of the literature was performed to ensure that wherever possible recommendations are supported by the results of clinical trials or substantive retrospective reports. Areas of uncertainty are indicated appropriately. CONCLUSION: Guidelines represent a consensus view of current best clinical practice. Where appropriate, key recommendations are given and the levels of evidence and strength of recommendation gradings are those used by the European Society for Medical Oncology (ESMO).
dc.formatPrint-Electronic
dc.languageeng
dc.language.isoeng
dc.publisherSPRINGERNATURE
dc.relation.ispartofBritish Journal of Cancer
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectScience & Technology
dc.subjectLife Sciences & Biomedicine
dc.subjectOncology
dc.subjectKINASE INHIBITOR THERAPY
dc.subjectPHASE-II TRIAL
dc.subjectIMATINIB MESYLATE
dc.subjectADJUVANT IMATINIB
dc.subjectCARNEY-STRATAKIS
dc.subjectPROGRESSION-FREE
dc.subjectDOSE IMATINIB
dc.subjectRISK
dc.subjectMUTATIONS
dc.subjectDIAGNOSIS
dc.titleGastrointestinal stromal tumour (GIST): British Sarcoma Group clinical practice guidelines.
dc.typeJournal Article
dcterms.dateAccepted2024-03-25
dc.date.updated2024-08-30T11:14:18Z
rioxxterms.versionVoR
rioxxterms.versionofrecord10.1038/s41416-024-02672-0
rioxxterms.licenseref.startdate2024-06-05
rioxxterms.typeJournal Article/Review
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/38840030
pubs.organisational-groupICR
pubs.organisational-groupICR/Primary Group
pubs.organisational-groupICR/Primary Group/ICR Divisions
pubs.organisational-groupICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-groupICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials
pubs.organisational-groupICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials (R Jones)
pubs.organisational-groupICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-groupICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials (R Jones)/Sarcoma Clinical Trials (R Jones) (hon.)
pubs.publication-statusPublished online
pubs.publisher-urlhttp://dx.doi.org/10.1038/s41416-024-02672-0
icr.researchteamSarcoma Clinical Trials
icr.researchteamTranslational Sarcoma, Melanoma and Rare Tumour Surgery
dc.contributor.icrauthorSmith, Myles
icr.provenanceDeposited by Mr Arek Surman on 2024-08-30. Deposit type is initial. No. of files: 1. Files: s41416-024-02672-0.pdf


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/